Genewin Biotech - Products

GENEWIN Biotech has been established at Hosur, Tamil Nadu - India in 2007 which is recognized by Department of Biotechnology (DBT), under NCS-TCP, Ministry of Science and Technology, Government of India is one of the major producers of good quality and disease free plants on a large scale, 5 million per year through Tissue culture Techniques and sells at the lowest price throughout India.

Spotlight

La Jolla Pharmaceutical Company

La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The Company has several product candidates in development. LJPC-501 is La Jolla’s proprietary formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension. LJPC-401 is La Jolla’s novel formulation of hepcidin for the potential treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease and myelodysplastic syndrome. LJPC-30S is our next-generation gentamicin derivative program that is focused on therapeutics for the potential treatment of serious bacterial infections as well as rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy.

OTHER VIDEOS

Image analysis software for true ultra high content data on the MACSima™ Imaging System

video | July 28, 2023

Qi Tissue Image Analysis Software for the MACSima™ Imaging Platform is the key to unlocking staggering analytical ability with ultra high content imaging data generated on the revolutionary new MACSima Imaging Platform....

Watch Now

Bioprinting Living Cells: The Next Frontier in Biotechnology Technology

video | July 30, 2023

Bioprinting with living human cells is transforming healthcare as we know it. From Slurpee-like substances to molding 3D tissues, explore the cutting-edge world of 3D bioprinting. Dr. Mark Skylar-Scott from Stanford University discusses the fascinating realm of 3D bioprinting, a groundbreaking approach that goes beyond traditional plastic printing....

Watch Now

VIA Thaw™ automated dry thawer

video | May 9, 2023

VIA Thaw™ dry automated thawers give you the confidence to reliably recover cryopreserved cellular products. VIA Thaw™ L1000 intended for research or manufacturing use only is an automated dry thawer that you can use for controlled, consistent thawing of cellular products in cryobags....

Watch Now

NeatCell C-Pro application software for the Sepax™ C-Pro instrument

video | May 9, 2023

Meet the NeatCell C-Pro application. It automates the mononuclear cell fraction enrichment from diverse cellular products, and is designed for use with a density-gradient medium like Ficoll-Paque media with the Sepax C-Pro instrument and CT-90.1 single-use kit....

Watch Now

Spotlight

La Jolla Pharmaceutical Company

La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The Company has several product candidates in development. LJPC-501 is La Jolla’s proprietary formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension. LJPC-401 is La Jolla’s novel formulation of hepcidin for the potential treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease and myelodysplastic syndrome. LJPC-30S is our next-generation gentamicin derivative program that is focused on therapeutics for the potential treatment of serious bacterial infections as well as rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy.

Events